Lactobacillus helveticus as Next Generation Probiotics
An emerging therapeutic approach that relies on microbiome regulation to treat or prevent pathogenic infections and inflammatory diseases is the live biotherapeutic product (LBP). Creative Biolabs’ goal is to commercialize its proprietary technology and engage with one or more corporate partners in the LBP industry. We will work with you as part of your team to provide you with not only comprehensive high-quality data, but also timely and effective solutions to any challenges you face.
Introduction of Lactobacillus helveticus (L. helveticus)
L. helveticus belongs to a group of organisms collectively known as lactic acid bacteria (LAB). This organism has a Generally Recognized as Safe (GRAS) status and displays many features that make it particularly suitable for dairy applications. L. helveticus strains are extensively used in the manufacture of Swiss-type cheeses and Italian cheeses, as well as fermented drinks. L. helveticus is also able to prevent gastrointestinal infections, enhance protection against pathogens, modulate host immune responses, and affect the composition of the intestinal microbiota.
Fig.1 Genetic maps of circular closed genomes of different L. helveticus strains. (Toropov, 2020)
L. helveticus for Disease Treatment
Oral administration of L. helveticus HY7801 prevented the development of collagen-induced experimental arthritis, and diminished disease progression and severity by reducing antigen-specific IgG levels and inflammatory immune response. Administration of L. helveticus HY7801 may induce regulatory CD11c+ dendritic cells, which in turn induce a phenotypic alteration of immune cells by reducing pro-inflammatory cytokines by CD4+ T cells. Therefore, oral immunomodulatory probiotics may be used as complementary and alternative functional drugs to treat inflammatory diseases in the future.
Scientists investigated the anti-inflammatory effects of hydrogen peroxide-producing lactic acid bacteria (LAB) on vulvovaginal candidiasis in β -estradiol immunosuppressed mice. The results showed that L. helveticus HY7801 (LH) most potently inhibited vulvovaginal candidiasis. LH also inhibited the expression of the pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6, and inflammatory enzymes, COX-2 and iNOS, as well as the activation of NF-κB. Based on these findings, LH may ameliorate vulvovaginal candidiasis by inhibiting the NF-κB pathway and candida albicans growth. In addition, L. helveticus may improve vulvovaginal candidiasis.
Fig.2 Effect of L. helveticus HY7801 on the expressions of pro-inflammatory and anti-inflammatory cytokines. (Joo, 2012)
What Services Can We Provide for L. helveticus at Creative Biolabs?
L. helveticus Related Products at Creative Biolabs
We supply a variety of L. helveticus strains of different preservation numbers as below. If you need other strains, please contact us.
-
Customized strain culture supernatant. (e.g.: for animal research)
-
Customized strain lyophilized powder containing certain CFU. (e.g.: for animal research)
At Creative Biolabs, we have the expertise to optimize each stage to ensure you get your desired outcome, achieving the highest levels of efficiency throughout. We are highly experienced in the analysis and development of LBP or probiotics. If you are interested in our L. helveticus related products or services, please feel free to contact us.
References
-
Toropov, V.; et al. Whole-genome sequencing of Lactobacillus helveticus D75 and D76 confirms safety and probiotic potential. Microorganisms. 2020, 8(3): 329.
-
Joo, H.M et al. Lactobacillus helveticus HY7801 ameliorates vulvovaginal candidiasis in mice by inhibiting fungal growth and NF-κB activation. International immunopharmacology. 2012, 14(1): 39-46.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
